CYP1A2 and glioblastoma: For example, the pharmacokinetic and pharmacogenomic studies of zotiraciclib conducted as part of the phase I trial for patients with recurrent glioblastoma and AA (NCT02942264) identified a single nucleotide polymorphism in the gene encoding CYP1A2 (CYP1A2_5347T>C, N541N, rs2470890), an enzyme that metabolizes zotiraciclib, which significantly altered the pharmacokinetics of the drug in a certain cohort of patients [69].